Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 8/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1241242 | 0.82 | ABCB1 (0.42) | GPR119MEN1KMT2ASRCABCB1 | |
| SCHEMBL4602385 | 0.81 | GPR119 (0.39) | GPR119MEN1KMT2ASRCABCB1 | |
| SCHEMBL2202034 | 0.81 | GPR119 (0.39) | GPR119MEN1KMT2ASRCABCB1 | |
| SCHEMBL7862914 | 0.79 | ABCB1 (0.41) | SRCABCB1PARP1 | |
| SCHEMBL3948290 | 0.79 | ABCB1 (0.41) | SRCABCB1PARP1 | |
| SCHEMBL12519664 | 0.77 | GPR119 (0.35) | GPR119SRCPARP1 | |
| SCHEMBL13662046 | 0.76 | ALDH1A1 (0.34) | MEN1KMT2ASRCABCB1PARP1 | |
| SCHEMBL3955172 | 0.76 | HDAC8 (0.38) | GPR119ABCB1 | |
| SCHEMBL9519428 | 0.75 | SRC (0.34) | MEN1KMT2ASRCABCB1PARP1 | |
| SCHEMBL12431668 | 0.75 | NR1H2 (0.37) | MEN1KMT2ASRCABCB1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969383-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8809380-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. | 2012-06-07 | — | — | US | disclosed |
| WO-2011016234-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | GPR119 2673/4885MEN1 3211/4885KMT2A 3369/4885 |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | GPR119 2673/4885MEN1 3211/4885KMT2A 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.